NeoStem, Inc. (NYSE MKT:NBS) and its subsidiary, Progenitor Cell Therapy LLC (“PCT”), together with Adaptimmune Limited and Adaptimmune LLC (collectively, “Adaptimmune”), announced today a Services Agreement under which PCT will provide services to support Adaptimmune’s NYESO-1c259-T cell therapy product being developed for multiple oncology indications (for more information with respect to Adaptimmune’s clinical trials, see clinicaltrials.gov, identifiers NCT01350401, NCT01343043 and NCT01352286).
Adaptimmune enters into Cell Therapy Manufacturing Services Agreement with NeoStem Subsidiary, Progenitor Cell Therapy.16 January 2013
- Pharma Live on 7th January – http://www.pharmalive.com/News/Index.cfm?articleid=873143
- BioPortfolio on 7th January – http://www.bioportfolio.com/news/article/1283578/Adaptimmune-Announces-Exclusive-License-With-Life-Technologies-Corporation-On-Proprietary-Manufacturing-Process.html
- BioSpace on 7th January – http://www.biospace.com/News/adaptimmune-ltd-announces-exclusive-license-with/284065
- Fierce Biotech on 8th January - http://www.fiercebiotechresearch.com/press-releases/adaptimmune-announces-exclusive-license-life-technologies-corporation-propr
- Pharmaceutical Business Review on 8th January – http://contractservices.pharmaceutical-business-review.com/news/adaptimmune-gains-licensing-rights-to-life-tech-antibody-coated-magnetic-beads-080113
- Technology Networks on 7th January - http://www.technologynetworks.com/news.aspx?id=147525
- Financial Times Weekend magazine on 11th January – http://www.ft.com/cms/s/2/a40f14fa-59fa-11e2-b728-00144feab49a.html#axzz2HlgR45m6
Exclusive License with Life Technologies Corporation on Proprietary Manufacturing Process for T Cell Therapy7 January 2013
Adaptimmune announces that it has secured an exclusive commercial license from Life Technologies Corporation for its intellectual property portfolio for methods of expanding and activating T cells transduced with engineered T cell receptors (TCR). Life’s Dynabeads® CD3/CD28 CTS™ are the only GMP-grade reagents commercially available for use in clinical trials practicing these patented methods for the rapid expansion of autologous T cells in T cell therapy.
- New Scientist online – with video – http://www.newscientist.com/article/dn22613-soupedup-immune-cells-force-leukaemia-into-remission.html
- BioSpace on 11 December – http://www.biospace.com/News/adaptimmune-ltd-announces-preliminary-results-from/282010
- Drug Discovery & Development on 12 December – http://www.dddmag.com/news/2012/12/adaptimmune-releases-myeloma-study-data
- BioPortfolio on 11 December – http://www.bioportfolio.com/news/article/1258787/Adaptimmune-Announces-Preliminary-Results-From-An-Early-Phase-Trial-Of-Gene-Engineered.html
- Clinica on 13 December – http://www.clinicaspace.com/News/adaptimmune-ltd-announces-preliminary-results-from/282279
- Biotechnology Europe on 10 December – http://www.biotechnology-europe.com/UK.html
- Pharma Live on 10 December – http://www.pharmalive.com/News/index.cfm?articleid=870546&categoryid=40#
- Technology Networks on 11 December – http://www.technologynetworks.com/RNAi/index.aspx
- Drugs.com Clinical Trials on 10 December – http://www.drugs.com/clinical_trials/adaptimmune-announces-preliminary-results-early-phase-trial-gene-engineered-t-cells-targeting-14848.html
- OBN on 10 December – http://www.obn.org.uk/obn_/news_item.php?r=PS3OWI518671
- Biocentury on 17 December – http://www.biocentury.com/weekinreview/clinicalresults/2012-12-17/enhanced-tcr-therapy-for-mm-preliminary-phase-iii-data-303336
Preliminary Results from an Early Phase Trial of Gene Engineered T Cells Targeting Cancer Testis Antigens in Multiple Myeloma10 December 2012
(Atlanta, GA and Oxford, UK) 10 December, 2012. Adaptimmune today announces the release of preliminary results from an early phase clinical study using patients’ own T cells that have been genetically altered to attack multiple myeloma (MM) cells. Lead investigators for the study presented today in three separate sessions at the annual meeting of the American Society of Hematology (ASH).
Adaptimmune announces the publication of dual abstracts in today’s issue of the Journal Blood, which report preliminary results from an early phase study using patients’ own T cells that have been genetically altered to attack multiple myeloma (MM) cells. Lead investigators for the study will be presenting the data on December 10th at the annual meeting of the American Society of Hematology (ASH).